Sermorelin Dosage: What the Evidence and Historical Filings Actually Show

Most pages that rank for "sermorelin dosage" hand back a single confident number — often 200 to 300 micrograms, sometimes a milligram figure, occasionally a chart that looks like it came from a package insert. The honest starting point is one this article checked directly rather than assumed: there is no current FDA-approved sermorelin label to read a dosage section off. Sermorelin's only approved brand, Geref, is discontinued, and a live search of DailyMed — the National Library of Medicine's own archive of FDA-approved drug labeling — returns zero results for it against a database published July 31, 2026¹. openFDA's own Drugs@FDA record confirms why: both of Geref's applications carry a marketing status of "Discontinued," with FDA's own note that the withdrawal was not for safety or effectiveness reasons². This article went one step further before writing anything: it fetched Drugs@FDA's own two archived documents for the older of Geref's two applications directly. Neither is a label. Both are 1990s manufacturing correspondence about environmental mold and yeast monitoring during production — Drugs@FDA's archive for this pre-1996 approval simply doesn't contain the labeling document at all, electronic or otherwise.

That's not a dead end, though — it's a reason to be precise about what actually is documented, rather than substitute a vendor's chart for a label that no longer exists.

The real number behind the historical approval: 30 µg/kg, by weight, not a flat dose

The regimen that produced Geref's pediatric approval is on the record, in a peer-reviewed trial rather than a label PDF. The Geref International Study Group's own pivotal multicenter trial — 110 previously untreated, prepubertal, growth-hormone-deficient children, treated for up to a year — used a single, explicit regimen: 30 micrograms per kilogram of body weight, once daily, injected subcutaneously at bedtime³. That's the actual historical dosing fact behind sermorelin's only FDA approval, sourced from the trial that established it, not inferred from a secondary chart. The same figure — 30 µg/kg SC — is repeated in this corpus's other primary source on sermorelin's approval history, alongside a second, separate regimen used only for diagnostic testing rather than ongoing treatment: a single 1 µg/kg intravenous dose, used to provoke and measure one GH pulse rather than sustain treatment over time⁴.

Two things about that 30 µg/kg figure matter for reading anything else claiming to describe "sermorelin dosage":

• •It's weight-based, not a flat milligram amount. A dose expressed per kilogram scales with the person taking it — which immediately makes any single fixed number claiming to be "the" sermorelin dose incomplete on its face.
• •It was established in prepubertal children with a diagnosed growth-hormone deficiency, dosed nightly for up to a year under a clinical trial protocol with regular safety monitoring — not in adults, and not for body-composition or wellness use.

What that dose would scale to at adult body weights — arithmetic, not a recommendation

Because 30 µg/kg is a per-kilogram figure, it's possible to see what it would translate to at typical adult body weights, purely as arithmetic on a published number — not as a suggestion that this ratio applies to adults, since no trial has tested it in adults. At 60 kg (about 132 lb), 30 µg/kg works out to 1.8 mg/day. At 70 kg (about 154 lb), 2.1 mg/day. At 90 kg (about 198 lb), 2.7 mg/day. Those are the pediatric weight-based ratio run forward on adult body weights, nothing more — the trial that generated the 30 µg/kg figure was never conducted in adults, and no clinical trial has established that the same ratio is appropriate, safe, or even meaningfully comparable outside the population it was tested in.

What actually circulates as an adult "sermorelin dosage" figure — and how far it sits from that arithmetic

Here is the part most pages skip entirely: a 2026 peer-reviewed narrative review in Frontiers in Endocrinology, written specifically to bridge "the gap between clinical evidence and patient self-administration" for exactly this category of compound, tabulates sermorelin's dosing picture in three separate rows rather than one. Alongside the same 1 µg/kg IV diagnostic figure and the same ~30 µg/kg SC historical treatment figure cited above, its table adds a third, explicitly separate line: what it labels a "bodybuilding-related forum" source reporting 200 to 300 micrograms subcutaneously, once daily, typically before bedtime on an empty stomach⁵. The review does not present that figure as clinical guidance — it presents it, by name, as what circulates in online self-administration protocols, set deliberately apart from the regulatory-grade evidence in the rows above it, as part of a broader project of giving clinicians a framework for interpreting what patients report actually doing.

Read the two numbers side by side rather than in isolation, because the gap between them is the actual finding here. A 200-300 µg flat dose is roughly six to ten times lower than the 1.8-2.7 mg (1,800-2,700 µg) that the pediatric weight-based ratio would project onto a 60-90 kg adult. That's not this article resolving which number is "right" — no trial has tested sermorelin at either figure in adults for wellness or body-composition use, so there is no controlled data establishing that either amount is safe or effective in that population. It's a documented, real discontinuity: the number that actually has a clinical trial behind it and the number that actually circulates in practice are not the same number, and treating either one as if it carries the other's evidentiary weight is the mistake this article is trying not to make.

What this site's own reviewed providers actually publish

Worth stating plainly, because it's checkable and it isn't invented: this site has reviewed seventeen telehealth and compounding providers that sell sermorelin². Every one of them publishes a monthly price. None of them publishes an actual microgram or milligram dosing schedule on their own product pages — the number a patient ultimately injects, at any of these providers, comes from an individual prescriber's intake process, not from a protocol printed on the site. That's a real gap between "how much this costs" and "how much you'd actually take," and it's one more reason a fixed number copied from a forum thread or a marketing page isn't a substitute for what a licensed prescriber determines for a specific patient.

This is informational, not a dosing recommendation

Nothing in this article is a suggestion of what dose to take. There is no current FDA label specifying a sermorelin dosage for any use. The 30 µg/kg figure describes a pediatric growth-hormone-deficiency trial protocol, administered under clinical supervision with scheduled safety monitoring, not a template for adult self-administration. The 200-300 µg figure describes what a peer-reviewed review reports circulating in unsupervised online protocols — reported as a documented phenomenon, not endorsed as safe or effective. If you have an actual prescribed dose from a licensed prescriber, our sermorelin reconstitution calculator will convert that number into the syringe volume it corresponds to — pure arithmetic on what you enter, never a substitute for what your prescriber determined or a suggestion of what that number should be. For who actually prescribes and compounds sermorelin, and how honestly each one discloses their pharmacy and regulatory category, our sermorelin provider rankings read those disclosures directly off each company's own site. Before deciding anything about the drug itself, our review of what sermorelin's trials, its drug class's current FDA label, and the cancer data actually report and our direct answer to whether sermorelin is safe are the companion reads on what taking it actually involves.

The bottom line

There is no current FDA-approved sermorelin label, confirmed live against both DailyMed and openFDA rather than assumed from sermorelin's history as Geref. What exists instead: a real, trial-sourced historical pediatric dose of 30 µg/kg/day subcutaneously at bedtime, a separate 1 µg/kg intravenous diagnostic-test dose, and — reported by a 2026 peer-reviewed review specifically studying the gap between clinical evidence and self-administration — a commonly circulating adult figure of 200-300 µg/day that sits far below what the pediatric ratio would project onto an adult body weight. None of those numbers is a recommendation. The gap between them is the most honest single fact this article has to offer: nobody has run the trial that would tell you which number, if either, is actually appropriate for an adult.